Bioretec has appointed Panu Mikkonen as chief financial officer from 6 October 2026, the fourth person to be named to the role since September 2025.

The appointment itself is quite routine. What stands out is the pattern around it: of roughly 400 management-team changes at Finnish listed companies that Listeds has tracked so far in 2026, Bioretec's finance function stands out for cycling through four CFOs (two of them interim) in just over a year, a pace uncommon for the role.

How the CFO role changed hands

Anne-Mari Matikainen took over as interim CFO with immediate effect on September 15, 2025, while outgoing CFO Johanna Salko stayed on to support the transition until her departure on November 30, 2025. Tuukka Paavola became permanent CFO on January 20, 2026, but Bioretec disclosed his departure barely six months later, on July 2, 2026. Anna-Mari Venola stepped in as interim CFO the same week to bridge to Mikkonen. Mikkonen is the fourth person to hold or be named CFO in roughly 13 months.

Frequent leadership changes cut two ways. Rapid turnover carries a cost of its own, in lost continuity and institutional memory, but replacing a poor fit quickly can equally signal decisiveness.

Two of the four moves were interim appointments, the usual way a company covers a gap while it searches, not four permanent hires that failed. Interim finance chiefs are in many cases also confirmed in the job later, though at Bioretec neither was made permanent.

All four CFO changes have unfolded under a single chief executive, Sarah van Hellenberg Hubar-Fisher, who became CEO after serving an interim position since May 2025, only in August 2025, weeks before the first of them; new chief executives often rebuild the finance function around themselves, and some of the turnover may reflect that. Bioretec has not disclosed the reasons behind each departure.

The backdrop he inherits

The finance turnover has run alongside an unsettled operating period. On October 31, 2025, Bioretec restated its first-half 2025 net sales, said it no longer expected accelerated growth, and withdrew its financial targets. Net sales then fell 12.6% to EUR 1.2 million in the first quarter of 2026. The company ran two rounds of change negotiations inside a year: one opened November 12, 2025 , a second in production concluded June 17, 2026 with three terminations.

Governance was reset in parallel: the May 8, 2026 Annual General Meeting re-elected five directors and added David Gill, resolved no dividend on a 2025 loss of EUR 7.87 million, and elected Kustaa Poutiainen as the Chairperson. The market registered the disruption: Bioretec's shares closed at EUR 0.083 on October 28, 2025, down from EUR 0.129 before the restatement three sessions earlier, on volume many times the daily average.

Mikkonen's mandate

On paper, Mikkonen fits the brief. He arrives with nearly 30 years across finance, business controlling, corporate development and strategic leadership, most recently as CFO of BPW Kraatz Group, where he ran finance and IT across Finland and the Baltics and worked as a strategic partner to management and the board. Earlier, he has held senior roles at Atoy Group and Nordcloud Group, and a master's in accounting from the Helsinki School of Economics, round out a career weighted toward cross-border finance operations and organisational change.

He reports to CEO Sarah van Hellenberg Hubar-Fisher and joins the management team. He succeeds Anna-Mari Venola, Bioretec's Controller, who has held the role on an interim basis since early July 2026.

Bioretec frames the hire around "international finance leadership, business transformation, and value creation"; that stress on transformation over steady-state stewardship reads as a signal of the kind of finance chief the company thinks it needs now.

Bioretec's target, set in December 2025, is to exceed EUR 10 million in net sales by 2028. The clearest positive in the period is regulatory: the RemeOs DrillPin received FDA Breakthrough Device Designation in December 2025 , building on RemeOs's first U.S. market authorization in March 2023 and its comprehensive CE mark in Europe in January 2025.

Mikkonen's brief, in the CEO's words, is to help "execute our growth strategy and expand globally". The nearer-term test is narrower: carrying a finance team through a full fiscal year without another departure. Whether he breaks that pattern will be the clearest early sign that Bioretec has steadied its finance function.

|

|

Leaders

Panu Mikkonen takes over as Bioretec's fourth CFO in just over a year

Panu Mikkonen takes over as Bioretec's fourth CFO in just over a year

·

5 min read

Explore and follow profiles from this article to get timely updates:

Credit: Bioretec

Credit: Bioretec

Bioretec has appointed Panu Mikkonen as chief financial officer from 6 October 2026, the fourth person to be named to the role since September 2025.

The appointment itself is quite routine. What stands out is the pattern around it: of roughly 400 management-team changes at Finnish listed companies that Listeds has tracked so far in 2026, Bioretec's finance function stands out for cycling through four CFOs (two of them interim) in just over a year, a pace uncommon for the role.

How the CFO role changed hands

Anne-Mari Matikainen took over as interim CFO with immediate effect on September 15, 2025, while outgoing CFO Johanna Salko stayed on to support the transition until her departure on November 30, 2025. Tuukka Paavola became permanent CFO on January 20, 2026, but Bioretec disclosed his departure barely six months later, on July 2, 2026. Anna-Mari Venola stepped in as interim CFO the same week to bridge to Mikkonen. Mikkonen is the fourth person to hold or be named CFO in roughly 13 months.

Frequent leadership changes cut two ways. Rapid turnover carries a cost of its own, in lost continuity and institutional memory, but replacing a poor fit quickly can equally signal decisiveness.

Two of the four moves were interim appointments, the usual way a company covers a gap while it searches, not four permanent hires that failed. Interim finance chiefs are in many cases also confirmed in the job later, though at Bioretec neither was made permanent.

All four CFO changes have unfolded under a single chief executive, Sarah van Hellenberg Hubar-Fisher, who became CEO after serving an interim position since May 2025, only in August 2025, weeks before the first of them; new chief executives often rebuild the finance function around themselves, and some of the turnover may reflect that. Bioretec has not disclosed the reasons behind each departure.

Our Pulse newsletter

Your weekly leadership intelligence briefing.

What happened, why it matters, and what to watch across every CEO, board, and executive move in Nordic listed companies, starting with Finland. Fast, factual, and to the point.

Delivered every Monday.

By signing up, you agree to our Privacy Policy

Our Pulse newsletter

Your weekly leadership intelligence briefing.

What happened, why it matters, and what to watch across every CEO, board, and executive move in Nordic listed companies, starting with Finland. Fast, factual, and to the point.

Delivered every Monday.

By signing up, you agree to our Privacy Policy

The backdrop he inherits

The finance turnover has run alongside an unsettled operating period. On October 31, 2025, Bioretec restated its first-half 2025 net sales, said it no longer expected accelerated growth, and withdrew its financial targets. Net sales then fell 12.6% to EUR 1.2 million in the first quarter of 2026. The company ran two rounds of change negotiations inside a year: one opened November 12, 2025 , a second in production concluded June 17, 2026 with three terminations.

Governance was reset in parallel: the May 8, 2026 Annual General Meeting re-elected five directors and added David Gill, resolved no dividend on a 2025 loss of EUR 7.87 million, and elected Kustaa Poutiainen as the Chairperson. The market registered the disruption: Bioretec's shares closed at EUR 0.083 on October 28, 2025, down from EUR 0.129 before the restatement three sessions earlier, on volume many times the daily average.

Mikkonen's mandate

On paper, Mikkonen fits the brief. He arrives with nearly 30 years across finance, business controlling, corporate development and strategic leadership, most recently as CFO of BPW Kraatz Group, where he ran finance and IT across Finland and the Baltics and worked as a strategic partner to management and the board. Earlier, he has held senior roles at Atoy Group and Nordcloud Group, and a master's in accounting from the Helsinki School of Economics, round out a career weighted toward cross-border finance operations and organisational change.

He reports to CEO Sarah van Hellenberg Hubar-Fisher and joins the management team. He succeeds Anna-Mari Venola, Bioretec's Controller, who has held the role on an interim basis since early July 2026.

Bioretec frames the hire around "international finance leadership, business transformation, and value creation"; that stress on transformation over steady-state stewardship reads as a signal of the kind of finance chief the company thinks it needs now.

Bioretec's target, set in December 2025, is to exceed EUR 10 million in net sales by 2028. The clearest positive in the period is regulatory: the RemeOs DrillPin received FDA Breakthrough Device Designation in December 2025 , building on RemeOs's first U.S. market authorization in March 2023 and its comprehensive CE mark in Europe in January 2025.

Mikkonen's brief, in the CEO's words, is to help "execute our growth strategy and expand globally". The nearer-term test is narrower: carrying a finance team through a full fiscal year without another departure. Whether he breaks that pattern will be the clearest early sign that Bioretec has steadied its finance function.

Follow moves like this on the Listeds Executive Intelligence Platform.

Board Programme

Built for Nordic listed company boards.

The only programme in the Nordics designed specifically for listed-company board work.
Five sessions, one cohort, twenty leaders in one room - Helsinki, 2026.

Board Programme

Built for Nordic listed company boards.

The only programme in the Nordics designed specifically for listed-company board work.
Five sessions, one cohort, twenty leaders in one room - Helsinki, 2026.

Authors

Founder and ceo

Helene Auramo is a co-founder of Listeds and Nordic Listed Leaders. She has previously co-founded Slush, Indiedays, Zipipop, and Okimo Clinic, building ventures at the intersection of media, technology, and community. She holds board positions at the Finnish Business School Graduates (Suomen Ekonomit) and Finnvera, and serves as Chair of the Investment Committee at the Finnish Business School Graduates. Helene is also a columnist for Talouselämä, Finland’s leading business magazine, and Aamulehti, one of the country’s largest newspapers. Her work focuses on leadership, growth, and the structures that shape decision-making in Nordic companies. She was awarded Future Board Member of the Year in 2022 by Future Board.

Founder and ceo

Helene Auramo is a co-founder of Listeds and Nordic Listed Leaders. She has previously co-founded Slush, Indiedays, Zipipop, and Okimo Clinic, building ventures at the intersection of media, technology, and community. She holds board positions at the Finnish Business School Graduates (Suomen Ekonomit) and Finnvera, and serves as Chair of the Investment Committee at the Finnish Business School Graduates. Helene is also a columnist for Talouselämä, Finland’s leading business magazine, and Aamulehti, one of the country’s largest newspapers. Her work focuses on leadership, growth, and the structures that shape decision-making in Nordic companies. She was awarded Future Board Member of the Year in 2022 by Future Board.

Sayali Mahurkar is a Junior Data and Business Analyst at Listeds, where she supports research, insights and data validation. She holds a Master’s in Statistics and Data Science, and has previously interned at Morgan Stanley and The Reserve Bank of India.

Sayali Mahurkar is a Junior Data and Business Analyst at Listeds, where she supports research, insights and data validation. She holds a Master’s in Statistics and Data Science, and has previously interned at Morgan Stanley and The Reserve Bank of India.

Authors

Founder and ceo

Helene Auramo is a co-founder of Listeds and Nordic Listed Leaders. She has previously co-founded Slush, Indiedays, Zipipop, and Okimo Clinic, building ventures at the intersection of media, technology, and community. She holds board positions at the Finnish Business School Graduates (Suomen Ekonomit) and Finnvera, and serves as Chair of the Investment Committee at the Finnish Business School Graduates. Helene is also a columnist for Talouselämä, Finland’s leading business magazine, and Aamulehti, one of the country’s largest newspapers. Her work focuses on leadership, growth, and the structures that shape decision-making in Nordic companies. She was awarded Future Board Member of the Year in 2022 by Future Board.

Sayali Mahurkar is a Junior Data and Business Analyst at Listeds, where she supports research, insights and data validation. She holds a Master’s in Statistics and Data Science, and has previously interned at Morgan Stanley and The Reserve Bank of India.

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

All Listeds newsletters (bundle)

One sign-up, the full picture.

Get every Listeds newsletter: the daily signal drumbeat, the weekly Pulse briefing, the monthly Best of the Month, the CEO letter, and the Weekend read.

By signing up, you agree to our Privacy Policy

Latest signalsLive feed
Moves trackerLive feed

Investor Event

Listeds Investor Event · Defence

Nordic defence is in a once-in-a-generation growth cycle. Eight listed and pre-IPO companies pitch to 100+ invited investors at Valkoinen Sali, Helsinki

21 September 2026

Latest on Listeds

Executive Intelligence

Ilmarinen is the first Defence Owner of the Year

Sep 21, 2026

Ilmarinen Mutual Pension Insurance Company was named Defence Owner of the Year 2026 on Monday evening at Valkoinen Sali in Helsinki, at the first Listeds Investor Event – Defence. The award is new, and so is the thing it measures. Not how much an institution owns, but what it has done with the ownership.

Finland has prizes for companies and prizes for chief executives. Owners have gone unrewarded.

“In Finland we reward companies and executives, but not owners. We wanted to create a category that measures an owner's actions: where the capital went, and what was done with the ownership”
Helene Auramo
Helene AuramoCEO, Listeds

The jury scored what Ilmarinen did, not what it held

The jury was chaired by Tiina Olkkonen, founder and chair of IR Partners, and included Sanna Andersson of Euroclear Nordics, Kyösti Jurvelin of Talouselämä and Klaus Ilmonen of Hannes Snellman.

Three things decided it. Ilmarinen anchored Reaktor's listing earlier this year and is now the company's largest institutional owner. It joined a funding round for the unlisted ICEYE. And it sits on the shareholders' nomination boards of roughly 40 Finnish listed companies every year, which is a direct lever on who ends up in those boardrooms.

“Defence capability is not created by public defence spending alone. Behind it you need competitive companies, innovation and patient private capital. In a changed security environment, institutional investors have an important role in making sure that defence and dual-use innovations born in Finland have the conditions to grow into internationally successful companies. That is why we wanted to reward an owner that does not merely invest in the sector but, through its own actions, is helping to build it.”
Tiina Olkkonen
Tiina OlkkonenChair of the jury, Founding Partner and Chair of IR Partners

That last point is the one the jury kept returning to. Defence and dual-use companies are growing quickly, and the competence their boards need is moving just as fast.

Eight companies pitched, five of them listed

Gofore, Kesla, Savox Communications and Aspocomp Group, all on Nasdaq Helsinki, and Betolar from Nasdaq First North pitched the defence and dual-use side of their businesses to a room of professional investors. Audicin, Njord and AGATE Sensors followed in the growth round with three minutes each.

Martti Wallin, venture partner at Sparkmind Capital and a past chairman of the Association of Finnish Defence and Aerospace Industries, opened the evening with a conversation on what investors and leaders get wrong about defence.

Leadership Moves

Juuso Pajunen joins Tieto from Terveystalo, and Finland's CFO chain runs one seat longer

Sep 18, 2026

Two stock exchange releases at 9:00 a.m. on 16 September moved one CFO between two Helsinki large caps that had cut guidance two days apart in July. Terveystalo named no successor and opened the search the same day — twelve days after handing Pajunen a second executive brief. Tieto filled the seat with a sitting CFO, which is the only way the job has been filled in Finland since December 2025.

Terveystalo and Tieto published matching stock exchange releases at 9:00 a.m. EEST on 16 September 2026. Pajunen, Terveystalo's Chief Financial Officer since November 2022, leaves on 15 December 2026 and joins Tieto by 1 January 2027 at the latest, reporting to Endre Rangnes. Terveystalo named no successor and opened the search the same day. The same Tieto release confirmed Johan Enger Nygaard at Tieto Tech Consulting and Bent Philipps at Tieto Indtech from 1 October, both interim since May 2026. 

Tieto's last first-time CFO is leaving; the next one arrives with the title

In August, Listeds counted atleast ten CFO changes across Nasdaq Helsinki and First North between December 2025 and August 2026. Every incoming CFO already held the title at another listed company. None was promoted from inside. None was taking the job for the first time. 

Tomi Hyryläinen, who steps down at the end of December 2026 after nearly eight years, joined Tieto in 2018 from PwC Finland, where he had been an assurance leader and partner. Tieto was his first listed-company CFO seat. Tieto has now filled it with a CFO already running finance at another Helsinki large cap, and before that at AFRY and Pöyry Group. 

Terveystalo widened Pajunen's job twelve days before losing him

Terveystalo reports in three segments today: Healthcare Services, Portfolio Businesses and Sweden. On 4 September it said Portfolio Businesses would be split from 1 January 2027, with Oral Health and Public Partnerships each becoming a reportable segment in their own right, and named Pajunen EVP of Portfolio Businesses until the end of 2026. He was covering for Henri Mäenalanen, who had announced on 29 June that he was leaving on 1 October to run Yliopiston Apteekki. Twelve days after taking the second brief, Pajunen announced his own exit. 

The date lands inside a crowded quarter. The EUR 574 million Silmäasema acquisition is expected to close by late 2026 or in the first quarter of 2027, the four-segment reporting starts on 1 January, and the Shareholders' Nomination Board must deliver its proposals by 1 February 2027. The CFO search runs across all of it.

Ville Iho put it in the company's own words: "Juuso has played a key role in the implementation of Terveystalo's profit improvement program and significant acquisitions, as well as in the development of financial leadership.”

One balance sheet is being levered up, the other handed back

Terveystalo reported first-half revenue of EUR 601.5 million, down 10.0%, adjusted operating profit of EUR 59.8 million, down 29.3%, and earnings per share of EUR 0.24, down 44.4%. On 15 July it cut 2026 adjusted operating profit guidance to EUR 120–140 million from EUR 135–165 million, against EUR 156.3 million delivered in 2025. It has raised its leverage ceiling to 3x net debt to adjusted EBITDA, cut dividend distribution to at least 50% of net result, and committed EUR 275 million in cash plus 36,500,000 new shares to Silmäasema, roughly 22.4% of shares outstanding after completion. 

Tieto reported second-quarter revenue of EUR 426.6 million, down 7.9%, with adjusted operating profit up 45.1% to EUR 63.4 million and margin at 14.9% against 9.4%. It cut its organic growth outlook on 17 July to between –5% and –3% and held the margin range at 14.8–15.8%. 

At Tieto he set the brief himself: "Tieto has a strong position in technological transformation and is well positioned for digital opportunities. At the same time, both Tieto and the entire industry are undergoing rapid changes, driven by AI. I am excited to join this fast-paced industry and believe that, with my broad experience across multiple businesses, I can contribute to the execution of Tieto’s ambitious strategy. As a CFO, I will focus on ensuring profitable growth and value creation while I believe that it all starts with culture." 

The audit committee chair moved between CFOs too

The annual general meeting on 24 March 2026 elected Petri Castrén, Kemira's Chief Financial Officer from 2013 to 2026 and its interim chief executive in 2023 and 2024. He chairs the audit committee, taking the seat from Kristian Pullola, formerly Nokia's and Finnair’s CFO, who left the board at the same meeting. 

What each company has committed to deliver

Terveystalo is running its ARC strategy toward adjusted earnings per share growth of 10% a year, leverage of no more than 3x and dividend distribution of at least 50% of net result. Nearer term it has to land 2026 adjusted operating profit inside EUR 120–140 million, close Silmäasema and capture the EUR 11–15 million of annual pre-tax run-rate synergies it has disclosed, complete the Solo Health acquisition in the first half of 2027. 

Tieto has to hold an adjusted operating margin of 14.8–15.8% while organic revenue contracts by 3% to 5%, finish resetting Tieto Tech Consulting by integrating Infopulse, Avega, EVRY India and Mentormate and reducing up to 500 roles, run the EUR 90 million buyback to March 2027.  That agenda is what the incoming CFO is being hired to pay for.

Terveystalo's next appointment is the cleanest test of the pattern

Whoever Terveystalo names will either confirm the August finding or be the first genuine exception to it, and the answer should arrive before the nomination board files its proposals on 1 February 2027. Watch also whether an interim covers the gap from 15 December, and how much of a handover Tieto gets: Hyryläinen leaves at the end of December and Pajunen arrives by 1 January at the latest. 

Join our Pulse, Best-of-the-Week, and Weekend newsletters

Join our Pulse, Best-of-the-Week, and Weekend newsletters